Vyome Secures USPTO Notice of Allowance for VT-1908 Ocular Inflammation Patent
HIND is trading near its 52-week low of $1.75 (8.6% above the low).
Summary
Vyome received a USPTO Notice of Allowance for its VT-1908 topical mycophenolate program, covering formulations and methods for treating inflammatory eye diseases. This is a meaningful IP milestone for a clinical-stage biotech with a $13.4M market cap, as it strengthens the company's patent position in a market it estimates at over $20B by 2035. The allowance follows peer-reviewed preclinical data published in February 2026 showing efficacy comparable to steroids in a uveitis model. While the patent has not yet issued and VT-1908 remains preclinical, the allowance validates the formulation's novelty and supports the company's broader ocular inflammation pipeline. Vyome's cash position was $7.9M as of Q2 2026, so this IP progress is a positive development for its valuation and potential partnering discussions.
At the time of this announcement, HIND was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.75 to $6.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.